Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Recommendation of "Buy" by Brokerages

Nkarta, Inc. (NASDAQ:NKTX - Get Free Report) has been given an average recommendation of "Buy" by the seven analysts that are presently covering the company, MarketBeat.com reports. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $15.00.

NKTX has been the topic of a number of analyst reports. HC Wainwright reduced their target price on shares of Nkarta from $22.00 to $18.00 and set a "buy" rating on the stock in a research note on Monday, November 11th. Needham & Company LLC reduced their target price on shares of Nkarta from $13.00 to $11.00 and set a "buy" rating on the stock in a research note on Friday, November 8th. Finally, Mizuho reduced their target price on shares of Nkarta from $20.00 to $16.00 and set an "outperform" rating on the stock in a research note on Thursday, November 21st.

Insider Activity

In other news, CEO Paul J. Hastings sold 17,378 shares of the business's stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $2.20, for a total value of $38,231.60. Following the sale, the chief executive officer now directly owns 319,859 shares of the company's stock, valued at approximately $703,689.80. The trade was a 5.15 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 8.70% of the company's stock.

Institutional Investors Weigh In On Nkarta

Institutional investors and hedge funds have recently made changes to their positions in the stock. Dimensional Fund Advisors LP increased its stake in Nkarta by 36.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 132,306 shares of the company's stock worth $782,000 after buying an additional 35,643 shares during the period. The Manufacturers Life Insurance Company increased its stake in Nkarta by 92.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,710 shares of the company's stock worth $122,000 after buying an additional 9,975 shares during the period. SG Americas Securities LLC purchased a new stake in Nkarta during the 3rd quarter worth approximately $93,000. GAMMA Investing LLC increased its stake in Nkarta by 110.9% during the 3rd quarter. GAMMA Investing LLC now owns 9,972 shares of the company's stock worth $45,000 after buying an additional 5,243 shares during the period. Finally, Intech Investment Management LLC purchased a new stake in Nkarta during the 3rd quarter worth approximately $74,000. 80.54% of the stock is owned by hedge funds and other institutional investors.

Nkarta Price Performance

NKTX traded up $0.09 on Tuesday, reaching $2.21. 675,431 shares of the company's stock were exchanged, compared to its average volume of 1,046,571. The stock has a market cap of $155.96 million, a PE ratio of -1.18 and a beta of 0.85. Nkarta has a twelve month low of $1.96 and a twelve month high of $16.24. The stock's fifty day moving average price is $2.36 and its 200-day moving average price is $3.66.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.